Hormone Replacement Therapy Increases Serum 1,25-dihydroxyvitamin D: A 2-year Prospective Study

Overview

Journal Calcif Tissue Int

Specialty Pathology

Date 1994 Dec 1

PMID 7895179

Citations 6

Authors

H J van Hoof

M J van der Mooren

L M Swinkels

R Rolland

T J BENRAAD

Affiliations

Soon will be listed here.

Abstract

Osteoporosis is a common disorder in postmenopausal women, which is probably due to decreased ovarian function. Currently, hormone replacement therapy (HRT), involving administration of estrogen and progestogen, is successfully applied to reduce bone resorption. We studied the effect of HRT on 23 postmenopausal women. This consisted of a combination of 17 beta-estradiol and dydrogesterone, on the serum level of 1,25-dihydroxyvitamin D (1,25(OH)2D) after 0, 6, 12, and 24 months. We found mean serum concentrations (+/- SD) of 1,25(OH)2D of 130.5 pmol/liter (46.1), 152.7 pmol/liter (45.1), 170.8 pmol/liter (64.0), and 155.2 pmol/liter (59.7), respectively. The baseline values in these women were found to be significantly lower than those during therapy (P < or = 0.005). No statistically significant differences were observed when comparing the estrogen-only phase with the combined estrogen-progestogen phase. It is concluded that HRT results in an increase in the serum 1,25(OH)2D concentration which lasts for at least 2 years. This increase may partly explain the preventive effect of HRT on osteoporosis. Furthermore, these results suggest that dydrogesterone does not influence the estrogen-induced changes in serum 1,25(OH)2D concentration.

Citing Articles

Vitamin D3 modulates the innate immune response through regulation of the hCAP-18/LL-37 gene expression and cytokine production.

Svensson D, Nebel D, Nilsson B Inflamm Res. 2015; 65(1):25-32.

PMID: 26433491 DOI: 10.1007/s00011-015-0884-z.

Vitamin D status among adults in Germany--results from the German Health Interview and Examination Survey for Adults (DEGS1).

Rabenberg M, Scheidt-Nave C, Busch M, Rieckmann N, Hintzpeter B, Mensink G BMC Public Health. 2015; 15:641.

PMID: 26162848 PMC: 4499202. DOI: 10.1186/s12889-015-2016-7.

Vitamin D status among Thai school children and the association with 1,25-Dihydroxyvitamin D and parathyroid hormone levels.

Houghton L, Gray A, Harper M, Winichagoon P, Pongcharoen T, Gowachirapant S PLoS One. 2014; 9(8):e104825.

PMID: 25111832 PMC: 4128742. DOI: 10.1371/journal.pone.0104825.

Determinants of serum levels of vitamin D: a study of life-style, menopausal status, dietary intake, serum calcium, and PTH.

Shirazi L, Almquist M, Malm J, Wirfalt E, Manjer J BMC Womens Health. 2013; 13:33.

PMID: 23945218 PMC: 3765227. DOI: 10.1186/1472-6874-13-33.

Physical activity in the prevention and amelioration of osteoporosis in women : interaction of mechanical, hormonal and dietary factors.

Borer K Sports Med. 2005; 35(9):779-830.

PMID: 16138787 DOI: 10.2165/00007256-200535090-00004.

References

Reginster J, Lecart M, Deroisy R, Sarlet N, Denis D, Ethgen D . Prevention of postmenopausal bone loss by tiludronate. Lancet. 1989; 2(8678-8679):1469-71. DOI: 10.1016/s0140-6736(89)92927-9. View

Prince R, Smith M, Dick I, Price R, Webb P, Henderson N . Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy. N Engl J Med. 1991; 325(17):1189-95. DOI: 10.1056/NEJM199110243251701. View

Lee J . Is natural progesterone the missing link in osteoporosis prevention and treatment?. Med Hypotheses. 1991; 35(4):316-8. DOI: 10.1016/0306-9877(91)90276-5. View

Riggs B, Hodgson S, OFallon W, Chao E, Wahner H, Muhs J . Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med. 1990; 322(12):802-9. DOI: 10.1056/NEJM199003223221203. View

Cheema C, Grant B, Marcus R . Effects of estrogen on circulating "free" and total 1,25-dihydroxyvitamin D and on the parathyroid-vitamin D axis in postmenopausal women. J Clin Invest. 1989; 83(2):537-42. PMC: 303712. DOI: 10.1172/JCI113915. View

Bikle D, Halloran B, Harris S, Portale A . Progestin antagonism of estrogen stimulated 1,25-dihydroxyvitamin D levels. J Clin Endocrinol Metab. 1992; 75(2):519-23. DOI: 10.1210/jcem.75.2.1639954. View

Tremollieres F, Pouilles J, Ribot C . Effect of long-term administration of progestogen on post-menopausal bone loss: result of a two-year, controlled randomized study. Clin Endocrinol (Oxf). 1993; 38(6):627-31. DOI: 10.1111/j.1365-2265.1993.tb02145.x. View

Hollis B . Assay of circulating 1,25-dihydroxyvitamin D involving a novel single-cartridge extraction and purification procedure. Clin Chem. 1986; 32(11):2060-3. View

van Hoof H, Swinkels L, van Stevenhagen J, van den Berg H, Ross H, BENRAAD T . Advantages of paper chromatography as a preparative step in the assay of 1,25-dihydroxyvitamin D. J Chromatogr. 1993; 621(1):33-9. DOI: 10.1016/0378-4347(93)80073-d. View

10.

Civitelli R, Gonnelli S, Zacchei F, Bigazzi S, Vattimo A, Avioli L . Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. J Clin Invest. 1988; 82(4):1268-74. PMC: 442678. DOI: 10.1172/JCI113725. View

11.

Lindsay R, Hart D, Aitken J, Macdonald E, Anderson J, Clarke A . Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet. 1976; 1(7968):1038-41. DOI: 10.1016/s0140-6736(76)92217-0. View

12.

Aloia J, Vaswani A, Yeh J, McGowan D, Ross P . Biochemical short-term changes produced by hormonal replacement therapy. J Endocrinol Invest. 1991; 14(11):927-34. DOI: 10.1007/BF03347118. View

13.

Kuhl H . Pharmacokinetics of oestrogens and progestogens. Maturitas. 1990; 12(3):171-97. DOI: 10.1016/0378-5122(90)90003-o. View

14.

Tilyard M, SPEARS G, Thomson J, Dovey S . Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med. 1992; 326(6):357-62. DOI: 10.1056/NEJM199202063260601. View

15.

Scheven B, Damen C, Hamilton N, Verhaar H, Duursma S . Stimulatory effects of estrogen and progesterone on proliferation and differentiation of normal human osteoblast-like cells in vitro. Biochem Biophys Res Commun. 1992; 186(1):54-60. DOI: 10.1016/s0006-291x(05)80774-0. View

16.

Kalu D, Salerno E, Liu C, Echon R, Ray M, Hollis B . A comparative study of the actions of tamoxifen, estrogen and progesterone in the ovariectomized rat. Bone Miner. 1991; 15(2):109-23. DOI: 10.1016/0169-6009(91)90002-h. View

17.

van der Mooren M, Demacker P, Thomas C, Borm G, Rolland R . A 2-year study on the beneficial effects of 17 beta-oestradiol-dydrogesterone therapy on serum lipoproteins and Lp(a) in postmenopausal women: no additional unfavourable effects of dydrogesterone. Eur J Obstet Gynecol Reprod Biol. 1993; 52(2):117-23. DOI: 10.1016/0028-2243(93)90237-7. View

18.

Riggs B, Melton 3rd L . Involutional osteoporosis. N Engl J Med. 1986; 314(26):1676-86. DOI: 10.1056/NEJM198606263142605. View

19.

Ishii T, Saito T, Morimoto K, Takeuchi Y, Asano S, Kumegawa M . Estrogen stimulates the elaboration of cell/matrix surface-associated inhibitory factor of osteoclastic bone resorption from osteoblastic cells. Biochem Biophys Res Commun. 1993; 191(2):495-502. DOI: 10.1006/bbrc.1993.1245. View

20.

Selby P, Peacock M . The effect of transdermal oestrogen on bone, calcium-regulating hormones and liver in postmenopausal women. Clin Endocrinol (Oxf). 1986; 25(5):543-7. DOI: 10.1111/j.1365-2265.1986.tb03607.x. View